There are many differences between the systematic erythalamus (SLE) as a complex self-immunizing disease, which can occur among children and adults.
In terms of clinical performance, systematic erythroacemia among children is usually more acute. Children are more likely to suffer from systemic symptoms, such as high heat, which can rapidly rise to 39°C or higher. This is different from the relatively high levels of low and moderate heat among adult patients. In the case of skin symptoms, although balms are more typical of children and adults, skin damage to children may be more widespread and severe. A child’s plate-shaped red spots may also appear in more places, and their colours may be more colorful and relatively slow to fade.
The kidney stress of children with systematic erythals is more pronounced. Almost all children suffer from different levels of kidney disease during the course of their illness, while among adults, kidney stress is relatively low. Protein urine may be more severe for children, and in some cases there may even be large amounts of protein urine, resulting in severe oedema, which spreads from the eyelids and lower limbs to the whole body and affects the normal development of the body. This is due to the fact that children ‘ s kidneys are still growing and developing, their own ability to regulate and repair is relatively weak, and they are more vulnerable to functional impairments in the event of a systematic attack on the erythmus.
In the blood system, anaemia, white-cell and plate reductions among children may occur earlier and more severely than among adults. As children are at the stage of growth and development, abnormalities in the blood system have a more significant impact on their physical functioning. For example, severe anaemia can make children paleer, prone to dizziness and inefficiency, and affect daily learning and activities; a reduction in slabs can lead to frequent nose bleeding, dental haemorrhage, etc., and cause greater disruption to the quality of life.
In terms of the impact of disease on growth and development, children are at greater risk of systemic red lupus. Because of the disease itself and the side effects of therapeutic drugs, children ‘ s normal growth and development are disrupted. For example, the long-term use of sugar cortex hormone treatment may affect the bone growth of children, resulting in a small body. Among adult patients, however, attention is focused on the long-term effects of disease on the functioning and quality of life of organs, less on growth and development issues.
In terms of laboratory tests, while both children and adult patients have anti-nuclear (ANA) positive status, child patients may have a higher rate of anti-bichain DNA antibodies and anti-Sm antibodies. The high positive rates of these specific antibodies help to detect and diagnose diseases earlier among children. Moreover, the drop in the C3 and C4 levels may be more pronounced among children, which also reflects a stronger response of the child immune system in the face of systematic attacks on red weeds.
In terms of treatment, systematic treatment of erythalamus by children is more challenging. Since children ‘ s bodies were still developing, more caution was needed in the choice and dosage of drugs. For example, when using immunosuppressants, both the control of disease development and the minimization of adverse effects on the growth and development of children are considered. The use of some drugs that may affect the functioning of the gland needs to be weighed more carefully among children. The main concern of adult patients in drug treatment is the efficacy and safety of the drug, which is not the relative focus of growth and development.
There are significant differences in clinical performance, developmental effects, laboratory examinations and treatment of systemic red lupus among children and adult systems. Understanding these differences is essential for better diagnosis, treatment and management of both types of patients.
